Ocular Therapeutix, Inc. (NASDAQ:OCUL) is Knoll Capital Management LLC’s 10th Largest Position

by · The Cerbat Gem

Knoll Capital Management LLC increased its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 199.6% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 600,400 shares of the biopharmaceutical company’s stock after purchasing an additional 400,000 shares during the period. Ocular Therapeutix comprises about 2.6% of Knoll Capital Management LLC’s portfolio, making the stock its 10th largest holding. Knoll Capital Management LLC’s holdings in Ocular Therapeutix were worth $5,223,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Ocular Therapeutix by 22.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 1,015 shares during the period. Essex Investment Management Co. LLC lifted its holdings in Ocular Therapeutix by 0.3% in the 3rd quarter. Essex Investment Management Co. LLC now owns 443,677 shares of the biopharmaceutical company’s stock worth $3,860,000 after purchasing an additional 1,168 shares in the last quarter. Amalgamated Bank lifted its holdings in Ocular Therapeutix by 37.9% in the 2nd quarter. Amalgamated Bank now owns 5,384 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 1,481 shares in the last quarter. Victory Capital Management Inc. raised its holdings in shares of Ocular Therapeutix by 36.9% during the 2nd quarter. Victory Capital Management Inc. now owns 17,403 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 4,695 shares in the last quarter. Finally, Atlas Capital Advisors LLC purchased a new stake in shares of Ocular Therapeutix during the 2nd quarter worth approximately $34,000. 59.21% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Robert W. Baird decreased their price objective on Ocular Therapeutix from $18.00 to $17.00 and set an “outperform” rating on the stock in a report on Thursday, August 8th. HC Wainwright raised their target price on shares of Ocular Therapeutix from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Finally, Scotiabank initiated coverage on Ocular Therapeutix in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $22.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $16.71.

Read Our Latest Research Report on OCUL

Insider Buying and Selling

In other Ocular Therapeutix news, insider Jeffrey S. Heier sold 2,948 shares of Ocular Therapeutix stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $9.01, for a total transaction of $26,561.48. Following the completion of the transaction, the insider now owns 269,059 shares in the company, valued at approximately $2,424,221.59. This trade represents a 1.08 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 3.50% of the stock is currently owned by company insiders.

Ocular Therapeutix Trading Up 3.2 %

Shares of OCUL opened at $10.06 on Friday. Ocular Therapeutix, Inc. has a 12 month low of $2.16 and a 12 month high of $11.77. The stock has a fifty day moving average price of $9.96 and a 200-day moving average price of $8.22. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19.

Ocular Therapeutix Profile

(Free Report)

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

Read More

Want to see what other hedge funds are holding OCUL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report).